Results 101 to 110 of about 2,262 (198)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection [PDF]

, 2018
Takayo Ueno, Mayu Osawa, Yasuhiko Imai, Hiroki Ishikawa, Tushar S. Garimella   +4 more
openalex   +1 more source

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)

, 2019
Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola, Li‐Qiang Sun   +3 more
openalex   +2 more sources

Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. [PDF]

J Viral Hepat
Suoh M, Esmaili S, Eslam M, George J.
europepmc   +1 more source

Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs. [PDF]

Molecules, 2023
Ren P, Li S, Wang S, Zhang X, Bai F.
europepmc   +1 more source

Synergistic antiviral effect of Asunaprevir and Ribavirin in combination against Murray Valley Encephalitis Virus replication

Gang Long, Guanglei Zhou, Nihua Dong, Julio Carrera Montoya, Wenlu Che, Xinya Ji, Luhe Gan, Jiayu Qian, Juncheng Chen, Na Liu, Jason M. Mackenzie   +10 more
openalex   +1 more source

Daclatasvir and asunaprevir improves health‐related quality of life in Japanese patients infected with hepatitis C virus [PDF]

, 2018
Hiroki Ikeda, Tsunamasa Watanabe, Nobuyuki Matsumoto, Tetsuya Hiraishi, Hiroyasu Nakano, Y. Noguchi, Nobuhiro Hattori, Ryuta Shigefuku, Masaki Yamashita, Kazunari Nakahara, Kotaro Matsunaga, Chiaki Okuse, Hiroshi Yotsuyanagi, Atsushi Tanaka, MICHIHIRO T. SUZUKI, Fumio Itoh   +15 more
openalex   +1 more source

Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. [PDF]

J Med Virol
Hirata S, Nogami E, Udono T, Fujisawa M, Tanaka Y.   +4 more
europepmc   +1 more source

[Real-world study of daclatasvir and asunaprevir combination in Chinese patients with HCV genotype 1b infection].

, 2018
J P Li, Wen-Chuang Feng, Zuo-Fu Xie, Mao Lei Xu, J Z Zhang, Yazhe Guan   +5 more
openalex   +2 more sources

Cost-Effectiveness Analysis of Daclatasvir in Combination with Asunaprevir (DUAL) for the Treatment of Chronic Hepatitis C Patients in China [PDF]

, 2018
Wenwu Cheng, W Chen
openalex   +1 more source

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source